Catherine Beech News Today

Exonate, an mRNA therapy company focused on treatments for diabetic complications, has announced that its lead ophthalmology asset, EXN407, has achieved its prespecified endpoints in an early study.

Exonate, an mRNA therapy company focused on treatments for diabetic complications, has announced that its lead ophthalmology asset, EXN407, has achieved its prespecified endpoints in an early study.

Exonate launches diabetic macular oedema trial 4th February 2021 Cambridge, UK-based Exonate has dose the first patient with its lead compound – EXN 407 – in a Phase Ib/II clinical trial investigating the drug in volunteers with centre-involved diabetic macular oedema (CI-DMO). The clinical trial, launched as part of Exonate’s collaboration with Janssen Pharmacueticals, consists of a dose escalation phase during which three doses of EXN 407 and a placebo will be tested. This will then be ...

Date Time Revolutionary eye drop trial starts for common eye diseases Research conducted by UNSW Sydney has paved the way for clinical testing of an eye drop treatment for diabetic macular oedema and wet age-related macular degeneration, the leading causes of blindness in the developed world. A clinical trial has commenced across Australia for a novel eye drop treatment that could improve the treatment of patients with retinal vascular diseases. If successful, the eye drops will revolutionise t...